{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:34:57Z","timestamp":1760240097605,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T00:00:00Z","timestamp":1552780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation.<\/jats:p>","DOI":"10.3390\/medicina55030071","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T12:18:53Z","timestamp":1552911533000},"page":"71","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report"],"prefix":"10.3390","volume":"55","author":[{"given":"Francesca Antonia","family":"Arcadi","sequence":"first","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Portaro","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giorgianni","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Naro","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4147","authenticated-orcid":false,"given":"Carmela","family":"Casella","sequence":"additional","affiliation":[{"name":"Stroke Unit, Policlinico Universitario, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Genovese","sequence":"additional","affiliation":[{"name":"Genovese Laboratory Medicine and Pathology, 98050 Barcellona PG, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Marino","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-3166","authenticated-orcid":false,"given":"Rocco Salvatore","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, 98123 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,17]]},"reference":[{"key":"ref_1","first-page":"486","article-title":"The anticardiolipin syndrome","volume":"13","author":"Hughes","year":"1986","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/327524a0","article-title":"Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor","volume":"327","author":"Palmer","year":"1987","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMcibr021805","article-title":"COX inhibitors and thromboregulation","volume":"347","author":"Marcus","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","volume":"359","author":"Furie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"ref_9","unstructured":"Neal, M.J. (2009). Medical Pharmacology at a Glance, Wiley-Blackwell. [6th ed.]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"951424","DOI":"10.1155\/2015\/951424","article-title":"Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches","volume":"2015","author":"Chighizola","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10072-011-0635-z","article-title":"Can interaction between atrial septal abnormalities and genetic prothrombotic polymorphisms play a role in cryptogenic ischemic stroke? Description of a family","volume":"33","author":"Gervasi","year":"2012","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MBC.0b013e3283485fc5","article-title":"Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a)","volume":"22","author":"Pezzini","year":"2011","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/MBC.0000000000000317","article-title":"A case of thrombosis of subcutaneous anterior chest veins (Mondor\u2019s disease) as an unusual complication of botulinum type A injection","volume":"26","author":"Pisani","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2017.06.001","article-title":"Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"190","author":"Hijazi","year":"2017","journal-title":"Am. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: Relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"985","article-title":"Dabigatran or warfarin in the treatment of acute venous thromboembolism in antiphospholipid syndrome","volume":"13","author":"Schulman","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.14017","article-title":"Use of direct oral anticoagulants in antiphospholipid syndrome","volume":"16","author":"Cohen","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5853\/jos.2015.17.3.366","article-title":"Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke","volume":"17","author":"Chung","year":"2015","journal-title":"J. Stroke"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","article-title":"Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo","volume":"12","author":"Perzborn","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_22","first-page":"e002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vene, N., Mavri, A., Gubensek, M., Tratar, G., Vizintin Cuderman, T., and Perme, M.P. (2016). Risk of thromboembolic events in patients with non-valvular atrial fibrillation after dabigatran or rivaroxaban discontinuation\u2014Data from the Ljubljana registry. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156943"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.case.2017.06.003","article-title":"Massive left atrial thrombi during dabigatran therapy for nonvalvular atrial fibrillation","volume":"1","author":"Bachvarova","year":"2017","journal-title":"Case"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","article-title":"Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack","volume":"48","author":"Coleman","year":"2017","journal-title":"Stroke"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0005-2795(77)90155-6","article-title":"A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients","volume":"494","author":"Friedman","year":"1977","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2010.03672.x","article-title":"Warfarin and vitamin K intake in the era of pharmacogenetics","volume":"70","author":"Lurie","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1345\/aph.1R179","article-title":"Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study","volume":"46","author":"Dager","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/NOR.0000000000000517","article-title":"A Review on the New and Old Anticoagulants","volume":"38","author":"Myers","year":"2019","journal-title":"Orthop. Nurs."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1538-7836.2010.03759.x","article-title":"New oral antithrombotics: A need for laboratory monitoring. Against","volume":"8","author":"Bounameaux","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/3\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:38:27Z","timestamp":1760186307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/3\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,17]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["medicina55030071"],"URL":"https:\/\/doi.org\/10.3390\/medicina55030071","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2019,3,17]]}}}